At present, various blood indicators have been evaluated for their prognostic roles in NSCLC patients with BM, such as neuron‐specific enolase (NSE) (26), carcinoembryonic antigen (CEA) (27), and Lung-molGPA (28). This evidence concerns the gene ENO2 and non-small cell lung carcinoma.